Repare Therapeutics Unveils Promising Phase 1 Results for Camonsertib

Repare Therapeutics Highlights Phase 1 Data for Camonsertib

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a prominent clinical-stage precision oncology company, has recently shared exciting data demonstrating the clinical advantages of camonsertib, a potentially leading oral small molecule ATR inhibitor, used in conjunction with palliative radiation for addressing metastatic tumors that contain an ataxia-telangiectasia-mutated (ATM) mutation.

Clinical Trial Overview

The data comes from a clinical trial conducted in collaboration with distinguished researchers at Memorial-Sloan Kettering Cancer Center. At a noteworthy session of the American Society for Radiation Oncology (ASTRO) annual meeting, Dr. Nancy Lee, a Radiation Oncologist and an Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center, presented the findings. The title of her presentation was, “Genotypically-Selected Pan Cancer Trial of Camonsertib with Palliative Radiation in the Treatment of Metastatic Tumors Harboring an ATM Mutation.”

Insights from the Phase 1 Study

“These promising early Phase 1 data provide further support for the widespread clinical potential of camonsertib,” said Dr. Maria Koehler, the Executive Vice President and Chief Medical Officer of Repare. “This initial human study, which combines camonsertib—an ATR inhibitor—with palliative radiation, showcases early clinical evidence suggesting that this combination may enhance radiosensitivity, leading to greater clinical benefits for patients with tumors containing pathogenic ATM mutations as compared to those with variants of unknown significance. We are highly motivated by this initial look at both the response rate and safety profile of this combination in the Phase 1 setting,” she added.

Key Study Findings

• A total of seventeen patients with metastatic tumors possessing ATM mutations participated in the trial. Among them, 12 were identified with pathogenic ATM mutations, while 5 had ATM mutations classified as variants of unknown significance (VUS).
• Primary cancer types documented included gastrointestinal (n=5), pancreas (n=5), breast (n=2), lung (n=2), bladder (n=2), and thyroid (n=1).
• The recommended phase 2 dose for camonsertib was established at 160 mg, administered once daily before radiation (4Gy) over five days.
• As of the submission date, interim response data was accessible for 16 patients:

• At the 2-month mark, 2 complete responses (CR), 5 partial responses (PR), and 4 stable disease (SD) cases were noted in the pathogenic ATM mutation group, with the VUS group showing 1 PR and 4 SD.
• At 6 months, among 9 evaluable patients, the pathogenic group reported 2 CR, 4 PR, and 1 SD versus the VUS group’s 1 SD and 1 progressive disease (PD).

About Repare Therapeutics

Repare Therapeutics stands out as a leading clinical-stage precision oncology company leveraging its proprietary synthetic lethality approach for both the discovery and development of innovative treatments. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform for systematically identifying and advancing precisely targeted cancer therapies that focus on genomic instability and DNA damage repair mechanisms. Their development pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor currently positioned in Phase 1/2 clinical development; camonsertib (RP-3500), a promising ATR inhibitor also in Phase 1/2 trials; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Pol? ATPase inhibitor; along with other undisclosed preclinical ventures. For further details, visit reparerx.com and join their community on social media.

Frequently Asked Questions

What is camonsertib?

Camonsertib is a novel oral small molecule ATR inhibitor that Repare Therapeutics is developing to enhance cancer treatment outcomes, especially when combined with other therapies.

What is the significance of the ATM mutation?

The ATM mutation is crucial because it significantly influences how tumors respond to therapies, particularly in relation to DNA damage repair mechanisms.

How many patients were involved in the trial?

A total of 17 patients with metastatic tumors harboring ATM mutations participated in the clinical trial.

What were the primary cancer types addressed in the study?

The study accounted for various cancer types, including gastrointestinal, pancreatic, breast, lung, bladder, and thyroid cancers.

Where can I find more information about Repare Therapeutics?

For more information about Repare Therapeutics and their innovative work in oncology, visit their official website at reparerx.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.